Source:http://linkedlifedata.com/resource/pubmed/id/21741592
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
2011-7-11
|
pubmed:abstractText |
BCL6 is a zinc-finger transcriptional repressor known for its oncogenic role in B cell lymphoma. In a recent issue of Nature, Duy et al. describe a novel role for BCL6 at the center of a transcriptional network in Ph(+) acute lymphoblastic leukemia cells that modulates their leukemogenicity and response to kinase inhibitors.
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:status |
PubMed-not-MEDLINE
|
pubmed:month |
Jul
|
pubmed:issn |
1878-3686
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright © 2011 Elsevier Inc. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:day |
12
|
pubmed:volume |
20
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
3-5
|
pubmed:year |
2011
|
pubmed:articleTitle |
BCL6: a novel target for therapy of Ph+ B cell acute lymphoblastic leukemia.
|
pubmed:affiliation |
Molecular Oncology Research Institute, Division of Hematology/Oncology, Tufts Medical Center, Boston, MA 02111, USA. rvanetten@tuftsmedicalcenter.org
|
pubmed:publicationType |
Journal Article,
Comment
|